Medtronic touts In.Pact Admiral drug-coated balloon data

Medtronic (NYSE:MDT) touted data for its In.Pact Admiral drug-coated balloon in patients with peripheral arterial disease. The company presented outcomes from its In.Pact Global study patient cohorts in Asia and Belgium, concluding that its DCB demonstrated consistent outcomes across patient populations.

More than 96% of the 114-patient study group in Asia achieved positive outcomes, which was consistent with results from the full global study cohort. Low clinically-driven target lesion revascularization at 1 year, nearly 4%, was also in line with the results of the 1,406 patients in the global study group.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic touts In.Pact Admiral drug-coated balloon data appeared first on MassDevice.

from MassDevice http://ift.tt/2ksT9Ol